comparemela.com

Neil Mcfarlane News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Zevra to Present Data from KP1077 Phase 2 Trial in IH at SLEEP

Zevra's CEO updates shareholders on recent milestones, including the completion of a phase 2 trial for idiopathic hypersomnia.

Zevra Therapeutics, Inc (NASDAQ:ZVRA) Q4 2023 Earnings Call Transcript

Zevra Reports Positive Phase 2 Results for IH Drug Candidate

Zevra Therapeutics announced positive topline results from its phase 2 clinical trial evaluating KP1077 for idiopathic hypersomnia (IH).

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.